Table 2.

Clinical findings of patients with in situ thrombosis.

Case	Clinical symptoms	Computed tomography	Echocardiography	PAG	Clinical outcome
1	DOE	Ground-glass opacity Diffuse patchy nodular interstitial opacity	Normal	Tapering vascular shadow of both upper lungs, mPAP = 30 mmHg	Oxygen therapy→improved
2	Polypnoea, hypoxemia	Ground-glass opacity Pleural effusion	mPAP = 70–75, 55 mmHg (under NO), RVH	—	Diuretics→severe PH→NO, PDE5i, PGI2→anticoagulants→improved
3	DOE, hypoxemia, polypnoea,	Ground-glass opacity	mPAP = 40–50 mmHg	—	NO, PDE5i, PGI2→anticoagulants, antithrombotic drugs→improved
4	Hypoxemia, sudden chest-abdominal pain	—	mPAP = 50–55 mmHg	—	Oxygen→sudden cardiopulmonary arrest (death)

DOE = dyspnea on exertion; mPAP = mean pulmonary artery pressure; PAG = pulmonary angiography; PDE5i = cGMP-specific phosphodiesterase type 5 inhibitor; PGI2 = prostaglandin I2; PH = pulmonary hypertension; RVH = right ventricular enlargement.